Home > Insider Trading > Filing (0000899243-19-030280)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598479	D Bob Brown	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-12-30	8,185	$3.42	17,855	No	4	M	Direct
Common Stock	Acquisiton	2019-12-30	4,951	$2.97	22,806	No	4	M	Direct
Common Stock	Disposition	2019-12-30	21,466	$21.84	1,340	No	4	S	Direct
Common Stock	Disposition	2019-12-30	1,340	$22.01	0	No	4	S	Direct
Common Stock	Acquisiton	2019-12-31	5,000	$3.42	5,000	No	4	M	Direct
Common Stock	Acquisiton	2019-12-31	11,941	$2.97	16,941	No	4	M	Direct
Common Stock	Disposition	2019-12-31	11,941	$22.00	5,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-30	8,185	$0.00	8,185	$3.42
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-30	4,951	$0.00	4,951	$2.97
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-31	5,000	$0.00	5,000	$3.42
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-31	11,941	$0.00	11,941	$2.97

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
106,659	2023-09-24	No	4	M	Direct
70,049	2027-01-03	No	4	M	Direct
101,659	2023-09-24	No	4	M	Direct
58,108	2027-01-03	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2019.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.45 to $22.17, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.17, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The option vested 1/48 monthly on last day of each month with the vesting start date of 7/30/2013.
The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.